Fri Sep 20 08:06:59 UTC 2024: ## Major Shareholder Sells Millions in BridgeBio Pharma Stock

**New York, NY – September 20, 2024** – Genetic Disorder L.P. Kkr, a major shareholder in BridgeBio Pharma, Inc. (NASDAQ:BBIO), sold 5.8 million shares of the company’s stock on Friday, September 13th. The shares were sold at an average price of $25.75, totaling $149.35 million. Following the transaction, the insider now directly owns 25,260,971 shares in the company, valued at over $650 million.

This transaction was disclosed in a filing with the Securities & Exchange Commission, which is available online. Major shareholders owning more than 10% of a company’s stock are required to disclose their transactions with the SEC.

BridgeBio Pharma, a commercial-stage biopharmaceutical company, focuses on developing treatments for genetic diseases and cancers. The company is currently in Phase 3 clinical trials for several products, including AG10 for the treatment of TTR amyloidosis and low-dose infigratinib for children with achondroplasia.

The sale of shares comes as BridgeBio Pharma continues to work towards bringing its products to market. It remains to be seen what impact this transaction will have on the company’s stock price.

**BridgeBio Pharma stock opened at $26.83 on Friday**, following a year with a low of $21.62 and a high of $44.32. The company’s market capitalization currently stands at $5.02 billion.

**Analysts** expect BridgeBio Pharma to post -2.49 earnings per share for the current fiscal year.

**Other recent transactions** in BBIO stock include purchases by YHB Investment Advisors Inc., Bfsg LLC, Quarry LP, Headlands Technologies LLC, and Assetmark Inc. Overall, 99.85% of the company’s stock is currently owned by institutional investors.

Read More